ホーム › 子宮内膜がん › オクラホマ › Oklahoma City
Oklahoma City、OKにおける子宮内膜がんの臨床試験
Oklahoma Cityとその周辺地域（約30マイル以内）の拠点で、子宮内膜がんに関する25件の研究が参加者を募集しています。研究を開いて、参加資格と連絡方法を確認してください。
公式研究テキスト（英語）
ここで研究参加者を募集していますか？ このページの上部に表示できます — 30日間 $99 →
Testing the Addition of an Antiangiogenic Drug (Bevacizumab) to Chemotherapy (Carboplatin and Paclitaxel) Combined With Immunotherapy (Pembrolizumab) for pMMR, TP53 Mutated Endometrial Cancer
被験者募集中第3相
- University of Oklahoma Health Sciences Center, Oklahoma City
Targeted Therapy Directed by Genetic Testing in Treating Patients With Locally Advanced or Advanced Solid Tumors, The ComboMATCH Screening Trial
被験者募集中第2相
- University of Oklahoma Health Sciences Center, Oklahoma City
The Evaluation of PC14586 in Patients With Advanced Solid Tumors Harboring a TP53 Y220C Mutation (PYNNACLE)
被験者募集中第1/2相
- University of Oklahoma, Oklahoma City
Testing Different Amounts of the Combination of Drugs M1774 and ZEN-3694 for the Treatment of Recurrent Ovarian and Endometrial Cancer
被験者募集中第1相
- University of Oklahoma Health Sciences Center, Oklahoma City
Study of AVZO-021 in Patients With Advanced Solid Tumors
被験者募集中第1/2相
- Avenzo Therapeutics Recruiting Site, Oklahoma City
Testing Nivolumab With or Without Ipilimumab in Deficient Mismatch Repair System (dMMR) Recurrent Endometrial Carcinoma
被験者募集中第2相
- University of Oklahoma Health Sciences Center, Oklahoma City
Study of REGN4018 (Ubamatamab) Administered Alone or in Combination With Cemiplimab in Adult Patients With Recurrent Ovarian Cancer or Other Recurrent Mucin-16 Expressing (MUC16+) Cancers
被験者募集中第1/2相
- Stephenson Cancer Center, Oklahoma City
Adjuvant Therapy in POLE-Mutated and p53-Wildtype/NSMP Early Stage Endometrial Cancer RAINBO BLUE & TAPER
被験者募集中第2相
- University of Oklahoma Health Sciences Center, Oklahoma City
Study of Elironrasib and Daraxonrasib as Monotherapies and Combination Therapy in Participants With Advanced KRAS G12C Mutant Solid Tumors
被験者募集中第1/2相
- University of Oklahoma, Oklahoma City
A Clinical Study of the Anti-cancer Effects of an Investigational Therapy or Chemotherapy in Patients With Recurring Uterine Cancer
被験者募集中第3相
- Peggy & Charles Stephenson Oklahoma Cancer Center, Oklahoma City
DESTINY-Endometrial01: A Phase III Study of Trastuzumab Deruxtecan Plus Rilvegostomig or Pembrolizumab as First-Line Treatment of HER2-Expressing (IHC 3+/2+), Mismatch Repair Proficient (pMMR) Endometrial Cancer
被験者募集中第3相
- Research Site, Oklahoma City
Phase 1, Safety and Tolerability Study of XmAb541 in Advanced Solid Tumors
被験者募集中第1相
- OU Health Stephenson Cancer Center, Oklahoma City
A Phase 2 Study of ACR-368 in Endometrial Adenocarcinoma
被験者募集中第2相
- Stephenson Cancer Center at OU Health, Oklahoma City
A Phase 1 Study of NRM-823 in Participants With Locally Advanced or Metastatic Refractory Solid Tumors
被験者募集中第1相
- Normunity Investigational Site, Oklahoma City
A Study of DM002 in Patients With Advanced Solid Tumors
被験者募集中第1/2相
- University of Oklahoma Health Sciences Center, Oklahoma City
Rinatabart Sesutecan (Rina-S, PRO1184, GEN1184) for Advanced Solid Tumors (GCT1184-01/ PRO1184-001)
被験者募集中第1/2相
- University of Oklahoma - Health Sciences Center, Oklahoma City
A Study of ART0380 for the Treatment of Advanced or Metastatic Solid Tumors
被験者募集中第1/2相
- Stephenson Cancer Center, Oklahoma City
A Study of Emiltatug Ledadotin (Emi-Le) in Participants With Solid Tumors
被験者募集中第1/2相
- Stephenson Cancer Center Oklahoma University Health, Oklahoma City
Predicting Response to Immunotherapy From Analysis of Live Tumor Biopsies (ELEPHAS-05)
被験者募集中観察研究
- Mercy Hospital - OKC, Oklahoma City
A Study of Targeted Agents for Patients With Recurrent or Persistent Endometrial Cancer
被験者募集中第1/2相
- University of Oklahoma Health Stephenson Cancer Center, Oklahoma City
Uterine Preservation Via Lifestyle Transformation
被験者募集中第2相
- University of Oklahoma, Oklahoma City
A Study of DR-0202 in Patients With Locally Advanced or Metastatic, Relapsed or Refractory Carcinomas
被験者募集中第1相
- Dren Investigational Site, Oklahoma City
Zanzalintinib in Combination With Paclitaxel in Recurrent High Grade Uterine Cancer
被験者募集中第1相
- University of Oklahoma, Oklahoma City
Trial of Nab-Sirolimus in Combination With Letrozole in Patients With Advanced or Recurrent Endometrioid Endometrial Cancer
被験者募集中第2相
- Oklahoma University Stephenson Cancer Center, Oklahoma City
A Study of Lifileucel (Tumor-infiltrating Lymphocytes) in Adults With Advanced Endometrial Cancer.
被験者募集中第2相
- University of Oklahoma, Oklahoma City
他の都市における子宮内膜がんの試験
- Houston, TX68件の研究
- New York City, NY52件の研究
- Boston, MA50件の研究
- Arlington, VA39件の研究
- Nashville, TN38件の研究
- Los Angeles, CA34件の研究
- St. Louis, MO29件の研究
- Philadelphia, PA28件の研究
- San Antonio, TX27件の研究
- Columbus, OH25件の研究
- Chicago, IL25件の研究
- Queens, NY25件の研究
Oklahoma Cityにおける他の研究
- 非小細胞肺癌28件の研究
- 卵巣がん28件の研究
- 大腸癌22件の研究
- 前立腺がん21件の研究
- 肺がん19件の研究
- 乳がん17件の研究
- 転移性癌16件の研究
- がん（全種類）14件の研究
- 急性骨髄性白血病14件の研究
- 頭頸部扁平上皮癌13件の研究
- 膀胱癌11件の研究
- 膵臓がん11件の研究
ClinicalTrials.govより、2026/10/06時点のデータを取得。各研究には独自の参加資格があり、参加可否は研究チームが決定します。